CDKN2A and breast cancer: Gauthier et al. have shown that women with a pathohistological diagnosis of ISC who express high p16 and high Ki67 develop a new tumor, and accordingly Ki67 classifies high p16 expression into two groups: those who develop subsequent breast cancer and another group of women who do not.